Reduction of Kaposi’s sarcoma-associated herpesvirus latency using CRISPR-Cas9 to edit the latency-associated nuclear antigen gene

Medicine & Life Sciences

• latency-associated nuclear antigen 97%
• Human Herpesvirus 8 73%
• Clustered Regularly Interspaced Short Palindromic Repeats 65%
• Kaposi's Sarcoma 33%
• Genes 23%
• HIV-1 9%
• Adenoviridae 7%
• Adenovirus Vaccines 5%
• Plasmids 5%
• Endothelial Cells 5%
• Epithelial Cells 5%
• Aptitude 4%
• Adenoviridae Infections 4%
• Nuclear RNA 4%
• Herpesviridae Infections 4%
• Gene Editing 4%
• Herpesviridae 4%
• Africa South of the Sahara 3%
• Efficiency 3%
• Nuclear Proteins 3%
• Human Herpesvirus 4 3%
• Mitosis 3%
• Viral Load 3%
• Infections 3%
• Developing Countries 3%
• HIV Infections 3%
• Epidemics 3%
• Acquired Immunodeficiency Syndrome 2%
• B-Lymphocytes 2%
• Survival Rate 2%
• Maintenance 2%
• Genome 2%
• Viruses 2%
• Neoplasms 2%
• Transplants 2%
• Cell Line 2%
• Safety 2%
• Therapeutics 1%

Agriculture & Biology

• Human gammaherpesvirus 8 100%
• nuclear antigens 89%
• sarcoma 36%
• genes 19%
• Adenoviridae 17%
• Human immunodeficiency virus 1 14%
• endothelial cells 7%
• epithelial cells 6%
• infection 6%
• Herpesviridae infections 6%
• neoplasms 5%
• plasmids 5%
• CRISPR-Cas systems 5%
• Human gammaherpesvirus 4 5%
• carrier state 4%
• gene editing 4%
• Herpesviridae 4%
• Sub-Saharan Africa 4%
• B-lymphocytes 3%
• developing countries 3%
• mitosis 3%
• cells 3%
• vaccines 3%
• survival rate 3%
• protein synthesis 2%
• cell lines 2%
• RNA 2%
• viruses 2%
• genome 2%
• methodology 1%